Abstract: Methods of preparing sterile de-cellularized human amniotic fluid that is amenable for long-term storage without loss of biological functions have been developed. In particular, the methods involve refrigeration steps to maximize shelf-life whilst retaining most of the important growth factors and other molecules present in the fresh amniotic fluid for effective therapeutic application. Use of the compositions is intended for therapeutic purposes and will alleviate pain or discomfort associated with any disorders or diseases, particularly those involving eyes and joints, or fibrotic disorders such as COPD.

Abstract: The present invention shows that CB plasma contains soluble NKG2D ligands and that the incubation of PBMCs with CB plasma results in decreased cytotoxicity, decreased proliferation and inhibition of IFNy production by NKG2D bearing cells, in particular, NK cells. Interaction of NKG2D with soluble NKG2D ligand leads to blocking of the NKG2D receptor, and renders NKG2D bearing cells refractory to activation and inhibits cell functions. Notably, this is a mechanism naturally employed by tumor cells or viruses such as CMV to escape the immune system.

Abstract: The present invention discloses novel ophthalmic preparations for the treatment of corneal pathologies comprising umbilical cord blood plasma.

Abstract: This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO2 or CO2 plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill oils by using supercritical CO2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.

Abstract: A butyrate-producing bacterium belonging to Anaerostipes hadrus is provided. The amount of butyrate produced is at least 1.5 times that of Anaerostipes hadrus YIT 10092T (DSM 3319T) and is measured by thawing a frozen stock solution of the bacterial strain (a 10% (w/v) skim milk-2% sodium glutamate solution with suspended bacterial cells) (cell count: 2.0 to 5.5×1010 cells/mL), inoculating the solution at 1% to 4 mL of a PY liquid medium supplemented with 33 mM sodium acetate and 0.5 (w/v) % glucose (PYGA medium), followed by anaerobic culture at 37° C. for 24 hours, then inoculating the culture solution at 1% to a PYGA medium, followed by anaerobic culture at 37° C. for 24 hours, then inoculating the culture solution at 1% to a PY medium containing 33 mM sodium acetate and 0.5 (w/v) % L-sorbose, followed by anaerobic culture at 37° C. for 24 hours, and then measuring the butyrate concentration.

Abstract: The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.

Abstract: The present invention relates to compositions such as an animal feed comprising one or more bacteria with fast germination and with anti-Clostridium perfringens effect.

Abstract: A combination comprising an effective dose of a chemotherapeutic-activating wild-type bacterium and an effective dose of a chemotherapeutic agent that is responsive to the chemotherapeutic activating wild-type bacterium, for use in a method of preventing or treating a solid tumour cancer in a mammal.

Abstract: The invention relates to direct-fed microbials for use in E. coli inhibition in animals. More particularly, the invention relates to isolated Bacillus strains 101, 235, 77, 177, and 102 and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use. The invention can also be used for treatment of plants and in food processing.

Abstract: Further enhancement in useful effects of Bifidobacteria. An oral composition comprising (A) Bifidobacterium breve MCC1274 (FERM BP-11175) and (B) at least one cruciferous vegetable selected from the group consisting of broccoli and cabbage.

Abstract: Methods and compositions for treating inflammatory bowel disease involve the use of targeted antibiotics in combination with probiotic formulations. The probiotics mitigate many of the deleterious side effects associated with antibiotic use and permit the antibiotic to be administered at a higher dose and for a longer duration than would otherwise be possible in the absence of the probiotic. The practice of the invention may reduce or eliminate the use of immunosuppressants in the treatment and management of IBD.

Abstract: The present invention relates to the combination of spirulina and palmitoylethanolamide (PEA) and/or pharmaceutically acceptable derivates or salts thereof, pharmaceutical formulations comprising the combination of spirulina and PEA and/or pharmaceutically acceptable derivates or salts thereof, optionally together with at least one physiologically acceptable excipient, and the use of the combination of spirulina and PEA and/or pharmaceutically acceptable derivates or salts thereof and formulations which include the said combination, for use in the prevention and/or treatment of tissue hyperactivation states, in the prevention and/or treatment of inflammatory pathologies, in the prevention and/or treatment of alterations in cardiac and/or coronary tissue, in the prevention and/or treatment of alterations in the vascular tissue, in the prevention and/or treatment of ophthalmic pathologies, preferably in the prevention and/or treatment of macular degeneration pathologies and glaucoma, in the prevention and/or tr

Abstract: It is to provide an agent for suppressing proliferation and/or inducing apoptosis of cancer cells that can be used for the treatment and chemoprophylaxis of cancer, wherein the agent is easily accessible and ingestible in daily dietary life and is prepared using a naturally-derived ingredient with reduced side effects, and a method for suppressing proliferation and/or inducing apoptosis of cancer cells in a subject in need thereof, and the like. By administering an agent for suppressing proliferation and/or inducing apoptosis of cancer cells comprising Sargassum horneri or a processed product thereof to a subject in need thereof, the proliferation of cancer cells can be inhibited and apoptosis of cancer cells can be induced in the subject.

Abstract: New extracts of Nannochloropsis sp. and related species of Nannochloropsis are suggested, obtainable by treating said microalgae with a solvent selected from the group consisting of C1-C1 aliphatic alcohols, ethyl acetate, water or their mixtures, removing the dissolved extracts from the residues and recovering the pure extracts from the solvent. The extracts show excellent properties particularly in modulating the metabolism of human skin and hair follicles.

Abstract: The present invention provides a drug combination for the treatment of infertility and its crude drug comprises the medical ingredients with their weight proportions listed as below: 10-20 amounts by weight of Rehmannia, 10-20 amounts by weight of Chinese Peony, 10-20 amounts by weight of Asiatic Dogwood, 10-20 amounts by weight of Chinese Yam, 10-20 amounts by weight of Poria, 15-25 amounts by weight of Astragalus, 15-25 amounts by weight of Codonopsis, 10-20 amounts by weight of Epimedium and 10-20 amounts by weight of Jujube. The compatibility of this drug combination invented is precise, appropriate and possess outstanding curative effects. As shown in many experiments, the drug combination invented is safe and reliable, its toxic & side-effect is low and it has obvious improvement effects on female infertility caused by androgen, fallopian tube inflammation, tubal blockage and other factors.

Abstract: Nutrient compositions comprising botanical extracts and an omega 3 fatty acid as well as methods of their use for treating, inter alia, autism or apraxia and/or ameliorating one or more symptoms thereof are disclosed. The use of such compositions for enhancing cognitive function and/or one or more aspects thereof, or for treating stroke or seizures and/or ameliorating one or more symptoms thereof are also disclosed.

Abstract: Topical aqueous compositions are effective in minimizing scar formation and improving the visual appearance of scars. The compositions are also effective in treating numerous skin disorders, including acne, psoriasis, and eczema.

Abstract: The invention relates to a method of decreasing blood sugar by inhibition of ?-glucosidase activity in a subject in need thereof, comprising administering pu-erh tea polysaccharides (PTPS) to the subject, wherein the active ingredients in PTPS are neutral sugar, protein, polyphenol, and uronic acids.

Abstract: The present invention relates to methods for improving muscle performance wherein a subject is administered an efficacious dose of a mixture of water soluble extracts of green and black tea. The invention also relates to a method of increasing antioxidant capacity and glutathione reductase while preventing the increased cortisol response in a subject and a method for improving testosterone levels in a subject following exercise, comprising the step of administering to a subject an efficacious dose of a mixture of water soluble extracts of green and black tea. Other aspects of the present invention relate to improving cortisol stress response and/or testosterone levels following exercise.

Abstract: Disclosed herein are green tea plant material extracts, and methods of using the extracts, comprising at least one green tea catechin selected from the group consisting of epi-gallocatechin, catechin, epicatechin, epigallocatechin-3-gallate, gallocatechin gallate, epicatechin-3-gallate, catechin gallate, and gallocatechin, wherein the compositions of the disclosure provide greater bioavailability of at least one green tea catechin.

Abstract: Disclosed are compositions and methods related to multivalent compositions targeted to cells and tissues. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.

Abstract: The present invention relates to a method of predicting the propensity of tripeptides to from aggregates in solution. The present invention also provides tripeptides which are able to form aggregates in solution, as well as uses thereof. The present invention also provides nanostructures formed by self-aggregation of tripeptides of the present invention. The present invention also provides pH responsive aggregates as well as methods of screening for the ability of a tripeptide to form a pH dependent aggregate or gel.

Abstract: Neurokinin 1 receptor (NK1R) agonist mediated protection of the eye is described. The protection can reduce dry eye and ocular infections, particularly in individuals with reduced NK1R activity.

Abstract: Compositions and methods for the prevention and treatment of blepharitis, where the compositions include verbascoside, oligopeptide-10, and sulfonated shale oil, and the preparation of such compositions.

Abstract: A method of treating or preventing a bacterial infection in an animal comprises administering to the animal an effective amount of an antibacterial peptide, the antibacterial peptide being derived from degraded date pits which are degraded by solid state degradation by a fungus, Trichoderma reesei. The antibacterial peptide has a molecular mass of less than 10 kDa and an amino acid sequence including (a) SEQ ID NO:4 or (b) SEQ ID NO:6. The bacterial infection is caused by a Gram-positive bacteria or a Gram-negative bacteria, for example, a Salmonella species, a Campylobacter species, a Shigella species, an Escherichia species, a Pseudomonas species, and a Staphylococcus species.

Abstract: Tumor cells exhibit consistent abnormalities in calcium regulation. The present disclosure teaches methods by which such differences are exploited to induce Apoptosis selectively in tumor/cancer cells while sparing normal cells. These methods are based upon employing drugs that, acting in synergistic combinations, trigger selective killing of malignant cells. Since the invention is based upon fundamental cell cycle requirements, to the extent that calcium handling abnormalities are a general characteristic of the malignant state, the methods presented here are widely applicable regardless of tissue of origin and degree of cellular de-differentiation.

Abstract: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases.

Abstract: Bioresorbable scaffolds for treatment of bifurcation lesion are described herein. Generally, an expandable scaffold may be fabricated from a high molecular weight isotropic PLLA material, wherein the scaffold incorporates one or more strain relief features which are configured to allow side branch treatment.

Abstract: Charged nutritive proteins are provided. In some embodiments the nutritive proteins an aqueous solubility of at least 12.5 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 50 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 100 g/L at pH 7.

Abstract: The present invention relates to a pharmaceutical composition, and more specifically, to a novel pharmaceutical composition for treating Alzheimer's disease including osmotin as an active ingredient.

Abstract: Disclosed are compositions and methods involving the use of PRG4 protein, also known as lubricin, to mechanically inhibit biological processes involving cell motility and adhesion. The methods and compositions may be used to develop a variety of specific therapies and compositions, often exploited through surgical procedures, where development of the pathology involves one or more of the following modes of action: 1) the passage of cells from one body compartment to another, 2) adherence of macrophages to substrates such as fibrin or exposed extra cellular matrix, 3) binding of platelets to fibrin, or 4) failure of function of the glycocalyx on exposed epithelial cell surfaces, e.g., within the vasculature.

Abstract: The invention relates to a polypeptide derived from the TSR (thrombospondin type 1 units) of SCO-Spondin for inhibiting or preventing apoptosis mediated by the cell death receptor ligands, such as TRAIL or FasL. The polypeptide of the invention comprises a sequence -W-S-A1-C-S-A2-C-G- wherein A1 and A2 are amino acid sequences comprising 1 to 5 amino acids. More particularly, the invention relates to said polypeptide for inhibiting or preventing the apoptosis associated with a disease selected from the group consisting of neurodegenerative disorders, cerebral ischemia, neuronal traumas, neuronal inflammatory diseases, and viral neurodegenerations.

Abstract: Disclosed is A method of treatment of a disorder or condition where it is desirable to inhibit the growth of cells, or a method of treatment which involves cytostatic therapy by administering an oligopeptidic compound to a subject in need thereof. The oligopeptidic compound is capable of interacting with proliferating cell nuclear antigen (PCNA) The compound comprises a PCNA interacting motif which is: which is: [K/R]-[F/Y/W]-[L/I/V/A/M]-[L/I/V/A/M]-[K/R] (SEQ ID NO. 28). The oligopeptidic compound has 9-70 subunits and at least one signal sequence. The signal sequence is a nuclear localization signal sequence and/or a cell penetrating signal sequence. In the compound a PCNA interacting motif is N-terminal to a signal sequence.

Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.

Abstract: CXCL12 polypeptide eluting matrices encapsulating at least one cell are described for use in the treatment of autoimmune disorders.

Abstract: Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13R?2, relative to the native human IL-13 protein; (b) altered affinity for IL-13R?1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4R? relative to the native human IL-13 protein.

Abstract: Methods of treating subjects having a disease or disorder responsive to IL-10, including methods of administration and dosing regimens associated therewith, are provided.

Abstract: Interleukin-15 muteins and other interleukin-15-related molecules are described, as well as methods of identifying interleukin-15 muteins and other interleukin-15-related molecules. Also described herein are modifications of the foregoing, which modifications may enhance a property (e.g., half-life) of the muteins or other molecules compared to human interleukin-15. Pharmaceutical compositions and methods of use are also described herein.

Abstract: A pharmaceutical formulation in a lyophilised form, which comprises pharmacologically effective amount of interferon beta-1a as an active ingredient, disaccharides as a bulking agent and a non-ionic surfactant. After reconstitution, the composition can be administered intravenously.

Abstract: The present invention relates to compositions of peptide and polypeptide analogs that are resistant to proteolysis, pharmaceutical uses thereof, and methods of preparation thereof.

Abstract: The present disclosure relates to the use of hepcidin in therapeutic methods for the treatment of various conditions in which decreasing serum iron concentration may be beneficial.

Abstract: To provide a therapeutic agent for gastrointestinal disorder such as diabetic gastroparesis. A postprandial gastrokinetic agent containing (A) ghrelin or a ghrelin agonist and (B) motilin or a motilin agonist as active ingredients, in which both the ingredients (A) and (B) are administered so as to act on the stomach after food intake.

Abstract: The present invention relates to a composition for modulating tumor cell dissemination, in particular metastatic cancer cells. In particular, the invention relates to an agent for modulating metastatic tumor cell dissemination for use in the treatment and/or prevention of a metastatic cancer wherein the agent an extracellular matrix (ECM) protein carried on a polycarbonate polyurethane matrix. The invention also relates to a product, comprising an agent for modulating metastatic tumor cell dissemination, and to a method of treatment or prevention of cancer.

Abstract: The invention is directed to methods of promoting myelin formation in central nervous system (CNS) tissue in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of interleukin-4 induced gene 1 (IL4-i1) protein. The invention is also directed to methods of monitoring the progression of conditions marked by an impairment of myelin formation in the CNS comprising assessing the levels or activity of IL4-i1 in activated macrophages obtained from the subject.

Abstract: A modified programmable nuclease provided as an antiviral therapeutic includes a programmable nuclease such as an RNA-guided nuclease, a DNA-guided nuclease, or a protein-guided nuclease linked to a secondary moiety to improve uptake, half-life, efficacy, or other properties. The nuclease is programmed to cleave viral genetic material in an infected patient.

Abstract: Compositions and methods are disclosed for reducing toxicity and immunogenicity of nucleases, especially when in use for cutting viral nucleic acids in host cells. Different nucleases that cut the same target are delivered at different times to avoid an immune response that interferes with a therapeutic effect of the nucleases.

Abstract: The present disclosure features methods and compositions for enhancing the ability of the respiratory membranes to filter airborne pathogens and protect a subject from respiratory infections that result from inhalation of such pathogens. In particular, the disclosure provides antimicrobial compositions that prevent and treat respiratory infections caused by bacteria, fungi, and viruses.

Abstract: The invention provides compositions and methods for effective lysosomal targeting mediated by SORT1. In particular, the compositions and methods provided by the invention may be used to treat lysosomal storage diseases such as Sanfilippo syndrome type B.

Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.

Abstract: A pharmaceutical preparation for the treatment of attention deficit disorders combines a therapeutically effective amount of digestive enzymes, such as chymotrypsin, and medication used to treat attention deficit disorders, such as Ritalin®, Concerta®, Adderall® and Strattera®. The preparation may be in the form of a tablet, capsule or time released formula in order to reduce the amount of pills per dosage. The pharmaceutical preparation ameliorates the symptoms of the attention deficit disorder. The preparation has a stabilizing matrix containing a solidified microcrystalline cellulose which captures and protects therapeutically effective amounts of digestive enzyme particles within the stabilizing matrix.